Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pseudoephedrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.69 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.69 |
| ▸ | RGS12 | O14924 | 1/20 | 0.69 |
| ▸ | GLA | P06280 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.69 |
| ▸ | HTR2A | P28223 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | THPO | P40225 | 1/20 | 0.69 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Racephedrine SCHEMBL1785211 | 1.00 | ADRA2C (0.69) | ADRA2CADRA1ACHRM2RGS12GLA | |
| Racephedrine SCHEMBL3079361 | 1.00 | ADRA2C (0.69) | ADRA2CADRA1ACHRM2RGS12GLA | |
| Pseudoephedrine SCHEMBL2081239 | 0.98 | ADRA2C (0.71) | ADRA2CADRA1ACHRM2RGS12GLA | |
| Racephedrine SCHEMBL2081241 | 0.98 | ADRA2C (0.71) | ADRA2CADRA1ACHRM2RGS12GLA | |
| Racephedrine SCHEMBL8017708 | 0.98 | ADRA2C (0.71) | ADRA2CADRA1ACHRM2RGS12GLA | |
| Pseudoephedrine SCHEMBL2323883 | 0.90 | ADRA2C (0.73) | ADRA2CADRA1ACHRM2RGS12GLA | |
| Pseudoephedrine SCHEMBL8728628 | 0.89 | ADRA2C (0.71) | ADRA2CADRA1ACHRM2RGS12GLA | |
| Racephedrine SCHEMBL8728630 | 0.89 | ADRA2C (0.71) | ADRA2CADRA1ACHRM2RGS12GLA | |
| Racephedrine SCHEMBL8862398 | 0.85 | CYP2D6 (0.96) | ADRA2CADRA1ACHRM2RGS12GLA | |
| Ephedrine SCHEMBL1997836 | 0.85 | CYP2D6 (0.96) | ADRA2CADRA1ACHRM2RGS12GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212205-B2 | Nucleic acid binding compounds and methods of use | UNIVERSITY OF ROCHESTER (US) | 2015-12-15 | — | — | US | disclosed |
| US-20140050778-A1 | NUCLEIC ACID BINDING COMPOUNDS, METHODS OF MAKING, AND USE THEREOF | UNIVERSITY OF ROCHESTER (US) | 2014-02-20 | — | — | US | disclosed |
| WO-2012092367-A1 | NUCLEIC ACID BINDING COMPOUNDS, METHODS OF MAKING, AND USE THEREOF | UNIVERSITY OF ROCHESTER (US) | 2012-07-05 | — | — | WO | disclosed |
| US-20100266677-A1 | NUCLEIC ACID BINDING COMPOUNDS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2010-10-21 | — | — | US | disclosed |
| WO-2009015384-A1 | NUCLEIC ACID BINDING COMPOUNDS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2009-01-29 | — | — | WO | disclosed |
| EP-1797083-A1 | SULFONAMIDE COMPOUNDS | Janssen Pharmaceutica, N.V. (BE) | 2007-06-20 | — | — | EP | disclosed |
| EP-1682537-A1 | MODULATORS OF CELLULAR ADHESION | Sunesis Pharmaceuticals, Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| WO-2006036670-A1 | SULFONAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-04-06 | — | — | WO | disclosed |
| WO-2005118584-A2 | SAFRAMYCIN ANALOGS AS THERAPEUTIC AGENTS IN THE TREATMENT OF CANCER | AXYS PHARMACEUTICALS, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005044817-A1 | MODULATORS OF CELLULAR ADHESION | SUNESIS PHARMACEUTICALS, INC. (US) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140050778-A1 | NUCLEIC ACID BINDING COMPOUNDS, METHODS OF MAKING, AND USE THEREOF | NSUN3, NSUN2, HNRNPF | SLC6A2 3995/4885ADRA2C 4693/4885ADRA1A 4591/4885 |
| US-20100266677-A1 | NUCLEIC ACID BINDING COMPOUNDS AND METHODS OF USE | SLIRP, HNRNPF, SUB1 | SLC6A2 3299/4885ADRA2C 4794/4885ADRA1A 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.